Ortho-Clinical gets rights to Roche cardiac assay
This article was originally published in Clinica
Roche Diagnostics has agreed to license to Ortho-Clinical Diagnostics, a Johnson & Johnson company, non-exclusive patent rights to its immunoassay technology designed to detect NT-proBNP (N-terminal prohormone brain natriuretic peptide), a key marker for congestive heart failure (CHF).
You may also be interested in...
Early results from the Low-Risk Bicuspid study of the Evolut transcatheter aortic valve replacement system showed low rates of all-cause mortality or stroke.
The reality is that many trials requiring hospital based tests and interventions cannot be replaced, but crisis will spur take up where practical.
The two companies announced more details about their COVID-19 vaccine development plan, including a $185m upfront payment and $113m equity investment from Pfizer.